Detalhe da pesquisa
1.
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
J Infect Dis
; 229(2): 413-421, 2024 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37506264
2.
Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
Clin Infect Dis
; 78(3): 562-572, 2024 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38036487
3.
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Clin Infect Dis
; 75(4): 690-701, 2022 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34864943
4.
Epidemiology of status epilepticus in the United States: A systematic review.
Epilepsy Behav
; 112: 107459, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33181886
5.
Burden of disease in patients with a history of status epilepticus and their caregivers.
Epilepsy Behav
; 112: 107374, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32882626
7.
Maribavir: Mechanism of action, clinical, and translational science.
Clin Transl Sci
; 17(1): e13696, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38071422
8.
A Phase 3 open-label study of the efficacy, safety and pharmacokinetics of buccally administered midazolam hydrochloride for the treatment of status epilepticus in pediatric Japanese subjects.
Epilepsy Res
; 174: 106651, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34020149